This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lubasch, A.
Right arrow Articles by Lode, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lubasch, A.
Right arrow Articles by Lode, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2600-2603, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers

Annette Lubasch,1,* Ivonne Keller,1 Klaus Borner,2 Peter Koeppe,3 and Hartmut Lode1

Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn,1 and Department of Medical Physics, Benjamin Franklin Hospital,2 Free University of Berlin, and Institute of Clinical Chemistry and Pathobiochemistry,3 Berlin, Germany

Received 18 November 1999/Returned for modification 18 March 2000/Accepted 15 June 2000

In an open, randomized, six-period crossover study, the pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin were compared after a single oral dose in 12 healthy volunteers (6 men and 6 women). The volunteers received 250 mg of ciprofloxacin, 400 mg of gatifloxacin, 600 mg of grepafloxacin, 500 mg of levofloxacin, 400 mg of moxifloxacin, and 200 mg of trovafloxacin. The concentrations of the six fluoroquinolones in serum and urine were measured by a validated high-performance liquid chromatography method. Blood and urine samples were collected before and at different time points up to 48 h after medication. Levofloxacin had the highest peak concentration (Cmax, in micrograms per milliliter) (6.21 ± 1.34), followed by moxifloxacin (4.34 ± 1.61) and gatifloxacin (3.42 ± 0.74). Elimination half-lives ranged from 12.12 ± 3.93 h (grepafloxacin) to 5.37 ± 0.82 h (ciprofloxacin). The total areas under the curve (AUCtot, in microgram-hours per milliliter) for levofloxacin (44.8 ± 4.4), moxifloxacin (39.3 ± 5.35), and gatifloxacin (30 ± 3.8) were significantly higher than that for ciprofloxacin (5.75 ± 1.25). Calculated from a normalized dose of 200 mg, the highest Cmaxs (in micrograms per milliliter) were observed for levofloxacin (2.48 ± 0.53), followed by moxifloxacin (2.17 ± 0.81) and trovafloxacin (2.09 ± 0.58). The highest AUCtot (in microgram-hours per milliliter) for a 200-mg dose were observed for moxifloxacin (19.7 ± 2.67) and trovafloxacin (19.5 ± 3.1); the lowest was observed for ciprofloxacin (4.6 ± 1.0). No serious adverse event was observed during the study period. The five recently developed fluoroquinolones (gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin) showed greater bioavailability, longer half-lives, and higher Cmaxs than ciprofloxacin.

* Corresponding author. Mailing address: Department of Chest and Infectious Diseases, Chest Hospital Heckeshorn, Zum Heckeshorn 33, D-14109 Berlin, Germany. Phone: 49 (0)30 8002 2222. Fax: 49 (0)30 8002 2623. E-mail: haloheck{at}zedat.fu-berlin.de.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2600-2603, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Von Groll, A., Martin, A., Jureen, P., Hoffner, S., Vandamme, P., Portaels, F., Palomino, J. C., da Silva, P. A. (2009). Fluoroquinolone Resistance in Mycobacterium tuberculosis and Mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53: 4498-4500 [Abstract] [Full Text]  
  • Dorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., Guy, E., Guyadeen, P., Leus, M. C., Maltas, G., Menzies, D., Nuermberger, E. L., Villarino, M., Vernon, A., Chaisson, R. E., the Tuberculosis Trials Consortium, (2009). Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 180: 273-280 [Abstract] [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Zeitlinger, M., Sauermann, R., Fille, M., Hausdorfer, J., Leitner, I., Muller, M. (2008). Plasma protein binding of fluoroquinolones affects antimicrobial activity. J Antimicrob Chemother 61: 561-567 [Abstract] [Full Text]  
  • Louie, A., Brown, D. L., Liu, W., Kulawy, R. W., Deziel, M. R., Drusano, G. L. (2007). In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3988-4000 [Abstract] [Full Text]  
  • Shaw, P. J., Hopfensperger, M. J., Ganey, P. E., Roth, R. A. (2007). Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-Alpha. Toxicol Sci 100: 259-266 [Abstract] [Full Text]  
  • Wagenlehner, F. M. E., Kinzig-Schippers, M., Tischmeyer, U., Wagenlehner, C., Sorgel, F., Naber, K. G. (2006). Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. Antimicrob. Agents Chemother. 50: 3947-3949 [Abstract] [Full Text]  
  • Sevillano, D., Aguilar, L., Alou, L., Gimenez, M.-J., Echevarria, O., Cafini, F., Valero, E., Fenoll, A., Prieto, J. (2006). Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: a pharmacodynamic in vitro model approach to selection of resistant populations. J Antimicrob Chemother 58: 794-801 [Abstract] [Full Text]  
  • Alou, L., Gimenez, M.-J., Sevillano, D., Aguilar, L., Cafini, F., Echeverria, O., Perez-Trallero, E., Prieto, J. (2006). A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother 58: 349-358 [Abstract] [Full Text]  
  • Malincarne, L., Ghebregzabher, M., Moretti, M. V., Egidi, A. M., Canovari, B., Tavolieri, G., Francisci, D., Cerulli, G., Baldelli, F. (2006). Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 57: 950-954 [Abstract] [Full Text]  
  • Waring, J. F., Liguori, M. J., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., Stachlewitz, R. F., North, C., Blomme, E. A. G., Roth, R. A. (2006). Microarray Analysis of Lipopolysaccharide Potentiation of Trovafloxacin-Induced Liver Injury in Rats Suggests a Role for Proinflammatory Chemokines and Neutrophils. J. Pharmacol. Exp. Ther. 316: 1080-1087 [Abstract] [Full Text]  
  • Washington, C. B., Hou, S. Y. E., Campanella, C., Hughes, N., Brown, S., Berner, B. (2005). Pharmacokinetics and Pharmacodynamics of a Novel Extended-Release Ciprofloxacin in Healthy Volunteers. J Clin Pharmacol 45: 1236-1244 [Abstract] [Full Text]  
  • Veziris, N., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V. (2005). Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. Antimicrob. Agents Chemother. 49: 4015-4019 [Abstract] [Full Text]  
  • Schuck, E. L., Grant, M., Derendorf, H. (2005). Effect of Simulated Microgravity on the Disposition and Tissue Penetration of Ciprofloxacin in Healthy Volunteers. J Clin Pharmacol 45: 822-831 [Abstract] [Full Text]  
  • Tachibana, M., Tanaka, M., Masubuchi, Y., Horie, T. (2005). ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES. Drug Metab. Dispos. 33: 803-811 [Abstract] [Full Text]  
  • Bauer, L. A., Black, D. J., Lill, J. S., Garrison, J., Raisys, V. A., Hooton, T. M. (2005). Levofloxacin and Ciprofloxacin Decrease Procainamide and N-Acetylprocainamide Renal Clearances. Antimicrob. Agents Chemother. 49: 1649-1651 [Abstract] [Full Text]  
  • Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., Plesiat, P. (2005). Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother 55: 518-522 [Abstract] [Full Text]  
  • Fuhrmann, V., Schenk, P., Jaeger, W., Ahmed, S., Thalhammer, F. (2004). Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 54: 780-784 [Abstract] [Full Text]  
  • Di Perri, G., Bonora, S. (2004). Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?. J Antimicrob Chemother 54: 593-602 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
  • Gajjar, D. A., Bello, A., Ge, Z., Christopher, L., Grasela, D. M. (2003). Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects. Antimicrob. Agents Chemother. 47: 2256-2263 [Abstract] [Full Text]  
  • Furlanut, M., Brollo, L., Lugatti, E., Di Qual, E., Dolcet, F., Talmassons, G., Pea, F. (2003). Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51: 101-106 [Abstract] [Full Text]  
  • Yoshimatsu, T., Nuermberger, E., Tyagi, S., Chaisson, R., Bishai, W., Grosset, J. (2002). Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis. Antimicrob. Agents Chemother. 46: 1875-1879 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»